What’s in Store for Endo 2013?

Dear Colleagues:

The Endocrine Society’s annual meeting, ENDO, fosters the dissemination of basic, translational, and clinical science and practice across the entire field of endocrinology.

The opportunity to hear and present the latest science and practice advances, and to network with other endocrinologists, has made ENDO a fixture on our members’ calendars. The Society’s Annual Meeting Steering Committee (AMSC) met in August to plan the scientific program for ENDO 2013, which will take place June 15–18 in San Francisco. The AMSC co-chairs—Didi Robins (overall chair), Dan Marks (basic science chair), and Mike Tuttle (clinical science chair)—led the committee in developing a spectacular program, with outstanding content for each of our constituencies.

As always, ENDO 2013 will offer opportunities to hear cutting-edge science and current advances in the diagnosis and treatment of endocrine diseases. With more than 75 symposia on breakthroughs in endocrinology and with more than 80 clinical Meet-the-Professor sessions, the ENDO 2013 program will cover the spectrum of endocrine research and its applications to patient care. In addition, ENDO 2013 will continue to offer the popular Master Clinicians Sessions, on topics such as type 2 diabetes, osteoporosis, and adrenal masses. The format of these sessions features two topic experts fielding questions from highly experienced clinicians for in-depth discussions of difficult cases. ENDO 2013 will also include basic and clinical Year In sessions. Basic Year In topics include “G Protein– Coupled Receptors (GPCRs)” and “Neuroendocrinology” and Clinical Year In topics include “Thyroid Cancer” and “Clinical Implications of Whole Genome Sequencing.” For a second year in a row, a half-day forum on GPCRs will be held in conjunction with ENDO 2013 to offer additional opportunities for detailed discussion of these important signaling molecules in endocrinology.

“Poster Preview Sessions” will debut this year to uniquely highlight research submitted in the form of abstracts. The posters will be selected from among the highest scoring abstracts and displayed as posters in each of the categories. Presenters will be invited to the podium to deliver a concise and compelling description of their work, with the goal of directing traffic to poster sessions.

The pre-ENDO Diabetes Diagnosis & Management Workshop will also be held in 2013. In addition to the outstanding scientific program, we will continue to take advantage of the opportunity ENDO offers to provide career development and networking for our students, fellows, and junior faculty. Special programming includes Endocrine Trainee Day: Class of 2013, Career Development Workshops, and the Presidential Poster Competition. In addition, selected junior investigators will be highlighted in Presidential Symposia that intermingle new with more established presenters. Providing a broad scope of latebreaking developments in endocrinology, ENDO 2013 is the must-attend meeting of the year. I look forward to seeing you in San Francisco for a very successful 95th Annual Meeting and Expo!

As always, I welcome your comments at president@endo-society.org.

William F. Young, Jr., M.D.
President, The Endocrine Society

You may also like

  • Introducing the New President: Gary D. Hammer, MD, PhD

    The Endocrine Society is pleased to welcome its president for 2020–2021, Gary D. Hammer, MD, PhD, who took office at the Society’s virtual business meeting on April 6. As director of the Endocrine Oncology Program at the University of Michigan Rogel Cancer Center in Ann Arbor, his work on adrenal homeostasis focuses on progenitor cell…

  • Moving Forward: Strategic Plan is Right on Track

    The Society always invites your questions, comments, and solutions for improvement. This year especially, we proactively sought input into our Fourth Strategic Plan (SP4). We surveyed our membership, held focus group meetings (targeting international members and past leaders), and interviewed “lapsed” members and outside stakeholders (e.g. insurers, deans, pharma). The resulting input fed into the…